Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Tourmaline Bio, Inc. - Common Stock (NQ: TRML )

16.85 -0.39 (-2.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 357,524
Open 17.26
Bid (Size) 14.00 (1)
Ask (Size) 17.37 (1)
Prev. Close 17.24
Today's Range 16.21 - 17.32
52wk Range 9.180 - 48.31
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
TRML Stock Earnings: Tourmaline Bio Beats EPS for Q2 2024
TRML stock results show that Tourmaline Bio beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Tourmaline Bio, Inc.
Via GlobeNewswire

Performance

YTD
-36.42%
-36.42%
1 Month
+3.12%
+3.12%
3 Month
+24.35%
+24.35%
6 Month
-57.61%
-57.61%
1 Year
+54.59%
+54.59%

More News

Read More
Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer
From Tourmaline Bio, Inc.
Via GlobeNewswire
TRML Stock Earnings: Tourmaline Bio Reported Results for Q4 2023
Via InvestorPlace
Tourmaline Bio to Present at the Jefferies Global Healthcare Conference
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial
From Tourmaline Bio, Inc.
Via GlobeNewswire
TRML Stock Earnings: Tourmaline Bio Beats EPS for Q1 2024
Via InvestorPlace
Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
From Tourmaline Bio, Inc.
Via GlobeNewswire
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
From Avalo Therapeutics
Via GlobeNewswire
Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Dow Jumps 200 Points; US Weekly Jobless Claims Fall
Via Benzinga
Topics Stocks
Exposures US Equities
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
Via Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Five Below Posts Q4 Results, Joins LexinFintech And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Announces Pricing of Public Offering of Common Stock
From Tourmaline Bio, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Tourmaline Bio Announces Proposed Public Offering of Common Stock
From Tourmaline Bio, Inc.
Via GlobeNewswire
Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)
From Tourmaline Bio, Inc.
Via GlobeNewswire
TDCX Receives Preliminary Non-binding Proposal Letter, Joins Pure Storage, Dyne Therapeutics And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Topics Stocks
Exposures US Equities
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
Via MarketBeat
Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.